You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
11 search results for: long-term
expert video
Long-term Impacts of AD and the Potential Benefit of Early Intervention
Dermatology
In this highlight video from the March 2024 AD symposium, Dr. Lawrence Eichenfield discusses the potential importance of early intervention in pediatric patients, and how addressing AD at an early stage may stop the clock on associated systemic comorbidities in the long term.
ADVENT On Air | Charting a New Course: The Frontier of Early Intervention and Disease Modification in AD
Dermatology
Join Drs. April Armstrong and Lisa Beck for a conversation around the long-term burden and effects of AD. They will discuss the underlying pathophysiology of AD and how early intervention and disease modification may impact disease course.
ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.
All rights reserved. MAT-US-2305040 v3.0-P Exp. Date: 11/24/2025
All Rights Reserved.
Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.